Mast cell tumours (MCTs) are the most common cutaneous malignancy in dogs, accounting for 16–21% of all canine skin tumours. Clinical behaviour varies enormously — low-grade MCTs with complete excision carry recurrence rates of less than 10%, while high-grade MCTs have a local recurrence rate of 36% even with complete surgical removal. The prognosis is largely determined by grade, margins, and the presence of lymph node or distant metastasis. Managing MCT after surgical excision is therefore a two-part challenge: monitoring the surgical site for local recurrence and monitoring systemically for lymph node or distant spread — the latter being the primary determinant of survival in high-grade disease.
Why MCT follow-up requires a grade-specific approach
The grade of the MCT — assessed by histopathology using either the Patnaik or Kiupel two-tier grading system — is the most important determinant of how intensive the follow-up needs to be. For low-grade (Kiupel) or grade I–II (Patnaik) MCTs with histologically complete surgical margins, the clinical risk in the first year is primarily local recurrence at the original site, with distant metastasis being uncommon. Follow-up at 1 month and 3 months post-surgery, with attention to the surgical site and regional lymph nodes, is the standard of care.
For high-grade or grade III MCTs — even those that appear to have been completely excised — the risk profile is substantially different. Recurrence rates of 36% have been documented even with complete margins. These dogs require more frequent monitoring, sentinel lymph node assessment, and consideration of adjuvant chemotherapy or radiation therapy. Histopathology that shows a high-grade MCT is the beginning of an oncological management conversation, not its conclusion.
The systemic risk from mast cell degranulation also warrants a specific mention. MCTs contain histamine and other vasoactive substances — degranulation can cause GI ulceration, hypotension, and anaphylactic reactions, particularly in dogs with large or manipulated tumours. Owners of dogs with MCTs — especially large, ulcerated, or multiple tumours — should be aware of these systemic effects and have H1 and H2 antihistamine support in place.
The mast cell tumour follow-up timeline
| Timepoint | What to check | Red flags |
|---|---|---|
| Day 10–14 | Surgical site healing, histopathology results reviewed with owner — grade, margins, mitotic index; suture removal; owner education about monitoring for new lumps | Incomplete margins on histopathology — discuss re-excision or radiation; owner not briefed on grade implications |
| 1 month post-surgery | Local recurrence check at surgical site, regional lymph node palpation, owner checking for new skin masses elsewhere, anti-histamine compliance | Local recurrence within 1 month — characteristic of high-grade disease; aggressive management needed urgently |
| 3 months post-surgery | Surgical site, all lymph nodes, full body lump survey by owner, thoracic radiographs and abdominal ultrasound for high-grade cases | New nodules at regional lymph nodes or distant sites — staging needed; owner has stopped routine skin checks |
| 6 months and 12 months | Complete physical exam, imaging for high-grade cases, owner-reported new lumps | Any new mass detected — FNA immediately for cytological assessment |
What to ask owners during MCT follow-up
- Have you been checking the surgical site regularly — does it look well healed?
- Have you felt any new bumps or lumps anywhere on [dog name]‘s body since the last visit?
- Have you been running your hands over the body systematically, as we discussed?
- Have you been giving the antihistamines as prescribed to manage any systemic mast cell effects?
- Has [dog name] had any episodes of vomiting, diarrhoea, or reduced appetite that might suggest GI ulceration from mast cell degranulation?
- Has he been scratching or showing skin reactions at the surgical site or elsewhere?
- Have the histopathology results been explained to you — do you understand what the grade means for monitoring intensity?
- For high-grade cases: has your oncology referral been made, and have you had a chest X-ray and abdominal ultrasound?
- Are you confident about what signs would prompt you to contact us urgently?
- Do you have your 3-month recheck appointment booked?
Common MCT follow-up mistakes clinics make
Not explaining grade implications in plain language. “Grade II with clean margins” and “Grade III with narrow margins” have vastly different clinical implications — but many owners leave the histopathology discussion without understanding what their dog’s grade means for recurrence risk, monitoring intensity, or adjuvant treatment options. A follow-up call at day 10–14, once histopathology results are available, that specifically explains what the grade means for next steps is the most important conversation in MCT management.
Not teaching owners how to do a systematic skin survey. Dogs with one MCT are at higher risk of developing subsequent MCTs. Owners who are taught a systematic approach — running their hands over the entire body including ventral abdomen, inside the legs, muzzle, and around the prepuce in males — and who do this weekly are more likely to detect new masses at a smaller, more surgically manageable size. A follow-up call that asks “have you been checking him regularly, and do you remember the areas to focus on?” reinforces this habit.
Under-monitoring high-grade cases in primary care. Dogs with grade III MCTs require thoracic radiographs and abdominal ultrasound at 3 months and 6 months post-surgery to detect pulmonary or visceral metastases. In practices without in-house oncology, this monitoring is often deferred until the dog becomes symptomatic. A proactive reminder system that schedules these imaging appointments at the appropriate intervals catches metastatic disease at an earlier and more treatable stage.
How to automate MCT follow-up without adding to your team’s workload
Nidana Loop schedules a day 10–14 histopathology results call, a 1-month local recurrence check, and a 3-month systemic monitoring reminder automatically for MCT cases. For high-grade cases, Loop schedules a 3-month imaging reminder with instructions for the owner on what the appointment involves. The calls ask specifically about new lumps, surgical site changes, and GI signs. The clinic sees a summary and urgent flag for any case where new masses or concerning systemic signs are reported.
See how Loop handles MCT follow-up calls → Book a 20-minute demo
Related: Chemotherapy follow-up · Mass removal aftercare · Lymphoma management follow-up